Olema Pharmaceuticals, Inc. (OLMA) investor relations documents from the company's IR site: 1 presentation, 7 press releases; latest deck 2026-08-01. Read in-app with summaries. First-party data.
Olema Corporate Presentation – August 2026: Olema Oncology is developing palazestrant and OP-3136 for metastatic breast cancer, targeting a $20B+ global market with a 2028 U.S. launch goal for palazestrant.
| Published | Type | Document |
|---|---|---|
| 2026-08-01 | Presentation | Olema Corporate Presentation – August 2026 |
| Press release | Olema Oncology Reports First Quarter 2026 Financial and Operating Results | |
| 2026-03-16 | Press release | Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results |
| Press release | Olema Oncology Reports Third Quarter 2025 Financial and Operating Results | |
| Press release | Olema Oncology Reports Second Quarter 2025 Financial and Operating Results | |
| Press release | Olema Oncology Reports First Quarter 2025 Financial and Operating Results | |
| 2025-03-18 | Press release | Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results |
| 2024-05-08 | Press release | Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update |
OLMA overview · OLMA earnings · OLMA financials · OLMA KPIs · OLMA documents · OLMA ownership · OLMA peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.